Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Tuesday session in red amid volatile trading. The shares closed down -0.27 points or -0.61% at $43.99 with 4.87 Billion shares getting traded. Post opening the session at $44.08, the shares hit an intraday low of $43.88 and an intraday high of $44.20 and the price vacillated in this range throughout the day. The company has a market cap of $109.14 Billion and the numbers of outstanding shares have been calculated to be 4.87 Billion shares.
On September 4, 2016 GlaxoSmithKline plc (ADR) (GSK) and Innoviva, Inc. (INVA) announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar® Ellipta® in patients with chronic obstructive pulmonary disease (COPD), compared with their ‘usual care’ administered in an everyday clinical practice setting. Data from the study are being presented at the European Respiratory Society (ERS) International Congress on Sunday 4th September in London, (abstract number OA249).
For the primary endpoint in patients, who had exacerbated in the year before the study, treated with Relvar Ellipta 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’) there was a statistically significant reduction of 8.4% (p=0.025; 95% CI 1.1 to 15.2) in the rate of moderate or severe exacerbations compared with patients receiving ‘usual care’. The majority of these patients in the study on usual care were taking an inhaled corticosteroid (ICS) containing regimen (88%). A similar reduction in exacerbations with FF/VI was seen in those patients on a treatment that included an ICS/ long-acting beta2-agonists (LABA) at baseline (8.0%; p=0.047; 95% CI 0.11 to 15.4).
For the ITT population there were no differences observed between FF/VI and usual care on secondary outcomes measured including the time to first moderate or severe exacerbation and rate of severe exacerbations, the rate of secondary care healthcare contacts and COPD related primary care contacts. There were more primary care contacts overall on FF/VI (12.3% increase, 95% CI 5.4 to 19.6). The COPD Assessment Test (CAT), which measures the impact of disease on health status, demonstrated 45% of patients receiving FF/VI improved their CAT score by 2 or more, a clinically relevant improvement, compared to 36% in the usual care group (odds ratio 1.51, 95% CI, 1.28 to 1.77).
Shares of CVS Health Corp (NYSE:CVS) ended Tuesday session in red amid volatile trading. The shares closed down -0.48 points or -0.51% at $93.36 with 1.07 Billion shares getting traded. Post opening the session at $93.97, the shares hit an intraday low of $92.90 and an intraday high of $94.08 and the price vacillated in this range throughout the day. The company has a market cap of $100.04 Billion and the numbers of outstanding shares have been calculated to be 1.07 Billion shares.
On Sept. 6, 2016 CVS Health, the nation’s largest pharmacy innovation company, launched an in-store fundraising campaign at CVS Pharmacy locations nationwide to benefit Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation, that supports innovative cancer research that gets new therapies to patients quickly to save more lives.
Through October 1, CVS Pharmacy customers can support SU2C by making a $1, $3 or larger donation at the register at 7,900 CVS Pharmacy locations or online at www.CVS.com/SU2C. The in-store fundraising campaign is part of a three-year, $10 million commitment by CVS Health to SU2C.
“With more than 1.6 million Americans diagnosed with cancer each year, we know many of our colleagues, customers and communities have been affected by this terrible disease,” said Helena Foulkes, President, CVS Pharmacy. “As part of our company’s purpose of helping people on their path to better health, we’re proud to support Stand Up To Cancer as they accelerate research and bring new therapies to patients.”
Donations made during the campaign will support SU2C’s collaborative cancer research model which helps bring new treatments to patients faster. SU2C’s “Dream Teams” bring together scientists from different institutions and across multiple disciplines to work together to translate their research from the laboratory to the patient.
“Because of partners like CVS Health, we’re able to make progress in increasing treatment options for patients and making advancements in the fight against cancer,” said SU2C co-founder Sue Schwartz. “We’re thankful for the support CVS Health has given to us over the past few years by giving its customers an easy way to make a donation and joining us in our mission of making everyone diagnosed with cancer a survivor.”